RegenxBio Inc (RGNX):企業の財務・戦略的SWOT分析

◆英語タイトル:RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1343
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,125見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,375見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

RegenxBio Inc (RGNX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC, is a clinical-stage biotechnology company that discovers and develops gene therapy for the treatment of various retinal, metabolic, and neurodegenerative diseases. The company develops, commercializes and licenses recombinant adeno-associated virus (AAV) gene therapy. Its products include AAV plasmids, AAV vector reporter systems and custom AAV vectors. RegenxBio employs its proprietary NAV technology platform, a gene delivery technology, to advance its product candidates. RegenxBio is headquartered in Rockville, Maryland, the US.

RegenxBio Inc Key Recent Developments

Apr 01,2020: REGENXBIO and Ultragenyx announce new license agreement for use of NAV technology platform for the treatment of Rare Metabolic Disorder
Feb 26,2020: REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights
Jan 09,2020: REGENXBIO reports continued progress across programs in year-end 2019 corporate update
Nov 05,2019: REGENXBIO reports third quarter 2019 financial and operating results and recent operational highlights

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
RegenxBio Inc – Key Facts
RegenxBio Inc – Key Employees
RegenxBio Inc – Key Employee Biographies
RegenxBio Inc – Major Products and Services
RegenxBio Inc – History
RegenxBio Inc – Company Statement
RegenxBio Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
RegenxBio Inc – Business Description
R&D Overview
RegenxBio Inc – Corporate Strategy
RegenxBio Inc – SWOT Analysis
SWOT Analysis – Overview
RegenxBio Inc – Strengths
RegenxBio Inc – Weaknesses
RegenxBio Inc – Opportunities
RegenxBio Inc – Threats
RegenxBio Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
RegenxBio Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 01, 2020: REGENXBIO and Ultragenyx announce new license agreement for use of NAV technology platform for the treatment of Rare Metabolic Disorder
Feb 26, 2020: REGENXBIO reports fourth quarter and full-year 2019 financial results and operational highlights
Jan 09, 2020: REGENXBIO reports continued progress across programs in year-end 2019 corporate update
Nov 05, 2019: REGENXBIO reports third quarter 2019 financial and operating results and recent operational highlights
Sep 30, 2019: REGENXBIO to present at The Chardan 3rd Annual Genetic Medicines Conference
Aug 07, 2019: REGENXBIO reports second quarter 2019 financial and operating results and additional positive interim phase I/IIa trial update for RGX-314 for the treatment of Wet AMD
Jul 24, 2019: REGENXBIO expands pipeline using NAV vectors to deliver therapeutic antibodies for the treatment of hereditary angioedema and neurodegenerative diseases
Jun 03, 2019: REGENXBIO selects Skyland PIMS as their process and product data management software system
May 15, 2019: REGENXBIO to Launch New Manufacturing Facility for NAV Technology-based AAV Gene Therapies
May 07, 2019: REGENXBIO Reports First Quarter 2019 Financial and Operating Results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
RegenxBio Inc, Key Facts
RegenxBio Inc, Key Employees
RegenxBio Inc, Key Employee Biographies
RegenxBio Inc, Major Products and Services
RegenxBio Inc, History
RegenxBio Inc, Subsidiaries
RegenxBio Inc, Key Competitors
RegenxBio Inc, Ratios based on current share price
RegenxBio Inc, Annual Ratios
RegenxBio Inc, Annual Ratios (Cont...1)
RegenxBio Inc, Annual Ratios (Cont...2)
RegenxBio Inc, Interim Ratios
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
RegenxBio Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
RegenxBio Inc, Performance Chart (2015 - 2019)
RegenxBio Inc, Ratio Charts
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[RegenxBio Inc (RGNX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Odakyu Electric Railway Co., Ltd. (9007):企業の財務・戦略的SWOT分析
    Odakyu Electric Railway Co., Ltd. (9007) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Grupo Bimbo, S.A.B. de C.V. (BIMBOA):企業の財務・戦略的SWOT分析
    Grupo Bimbo, S.A.B. de C.V. (BIMBOA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • San Miguel Brewery Hong Kong Ltd.:企業の戦略・SWOT・財務分析
    San Miguel Brewery Hong Kong Ltd. - Strategy, SWOT and Corporate Finance Report Summary San Miguel Brewery Hong Kong Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • OyaGen Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary OyaGen Inc (OyaGen) is a biotechnology company that discovers, develops and commercializes novel pharmaceutical therapies. The company offers viral infectivity factor Dimerization Antagonist, Vif Interaction with APOBEC3G, Vif dependent polyubiquitination of APOBEC3G and APOBEC3G activators. …
  • Impact Developer & Contractor SA:企業の戦略・SWOT・財務情報
    Impact Developer & Contractor SA - Strategy, SWOT and Corporate Finance Report Summary Impact Developer & Contractor SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • IRPC Public Company Limited:企業の戦略・SWOT・財務分析
    IRPC Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary IRPC Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Iconic Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Iconic Therapeutics Inc (Iconic Therapeutics) is a biopharmaceutical company that provides translation of scientific insight into breakthrough medicines. The company offers development of tissue factor in inflammation, angiogenesis, and metastasis that led to develop new approach to retinal …
  • Steel Authority of India Ltd:企業のM&A・事業提携・投資動向
    Steel Authority of India Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Steel Authority of India Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Calix, Inc. (CALX):企業の財務・戦略的SWOT分析
    Calix, Inc. (CALX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Arris International Plc
    Arris International Plc - Strategy, SWOT and Corporate Finance Report Summary Arris International Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • China Petroleum & Chemical Corp (600028):石油・ガス:M&Aディール及び事業提携情報
    Summary China Petroleum & Chemical Corp (Sinopec Corp), a subsidiary of China Petrochemical Corporation, is a vertically integrated energy and chemical company. It is involved in the oil and gas exploration and production, extraction, pipeline transmission and marketing; oil refining; and production …
  • Air Products and Chemicals Inc (APD):企業の財務・戦略的SWOT分析
    Air Products and Chemicals Inc (APD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • RPP Infra Projects Ltd (RPPINFRA):企業の財務・戦略的SWOT分析
    RPP Infra Projects Ltd (RPPINFRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Group Five Ltd:企業の戦略的SWOT分析
    Group Five Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Callitas Therapeutics Inc (LILY):製薬・医療:M&Aディール及び事業提携情報
    Summary Callitas Therapeutics Inc (Callitas Therapeutics), formerly M Pharmaceutical Inc, is a drug discovery and development company that offers ground-breaking drug treatments and biomedical technologies. The company’s products include weight management products, infertility products and women’s h …
  • Mitsubishi Estate Co., Ltd. (8802):企業の財務・戦略的SWOT分析
    Mitsubishi Estate Co., Ltd. (8802) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Biotronik SE & Co KG:企業の戦略的SWOT分析
    Biotronik SE & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Fluor Corp (FLR)
    Fluor Corp (FLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Sterlite Technologies Ltd (STRTECH):企業の財務・戦略的SWOT分析
    Summary Sterlite Technologies Ltd (Sterlite), a subsidiary of Vedanta Resources plc is a technology company that manufactures and markets power and telecom products and solutions. The company offers a wide range of data cables for structured cabling. Sterlite's application services include data cent …
  • Arch Therapeutics Inc (ARTH):医療機器:M&Aディール及び事業提携情報
    Summary Arch Therapeutics Inc (Arch Therapeutics) is a medical device company that develops self-assembling barrier technologies to improve interventional wound care outcomes. The company offers hemostasis and sealant products to seal and protect leaking and bleeding tissue. It provides intervention …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆